A na-eji Relugolix agwọ ọrịa kansa prostate na ụmụ nwoke.
Aha ika: Orgovyx
Klas ọgwụ ọjọọ: Antineoplastic - LHRH (GnRH) Ndị na-emegide Pituitary Suppressants
Nnweta: Achọrọ ndenye ọgwụ
Ime ime: Gwa dọkịta gị. Ọgwụ a nwere ike imebi nwa e bu n'afọ.
Lactation: kpọtụrụ dọkịta tupu iji

Relugolix bụ homonụ nke na-ewepụta gonadotropin na-abụghị peptide (GnRH ma ọ bụ luteinizing hormone na-ahapụ homonụ (LHRH), nke nwere ọrụ antineoplastic. Relugolix na-ejikọ aka ma na-egbochi GnRH nnabata na pituitary gland, nke na-egbochi njikọ GnRH na onye na-anabata GnRH ma na-egbochi nzuzo na mwepụta nke hormone luteinizing (LH) na follicle stimulating hormone (FSH). N'ime ụmụ nwoke, mgbochi nke nzuzo nzuzo LH na-egbochi ntọhapụ nke testosterone site na mkpụrụ ndụ Leydig na testes. Ebe ọ bụ na a chọrọ testosterone iji kwado uto prostate, ibelata ọkwa testosterone nwere ike igbochi mmụba cell prostate na-adabere na hormone.

Relugolix bụ homonụ na-ewepụta gonadotropin (GnRH) antagonist nke ejiri na ọgwụgwọ ọtụtụ ọnọdụ na-anabata homonụ. Ebu ụzọ kwado ya na Japan na 2019, n'okpuru akara aha Relumina, maka ọgwụgwọ symptomatic nke uterine fibroids, na nso nso a site na United States 'FDA na 2020, n'okpuru aha Orgovyx, maka ọgwụgwọ ọrịa kansa prostate dị elu. A mụọkwara Relugolix na ọgwụgwọ mgbaàmà nke endometriosis. Relugolix bụ nke mbụ (na ugbu a naanị) onye na-anabata GnRH na-anabata ọnụ nke akwadoro maka ọgwụgwọ ọrịa kansa prostate - ọgwụgwọ yiri ya dị ka [degarelix] chọrọ nchịkwa subcutaneous - yabụ na-enye nhọrọ ọgwụgwọ dị obere arọ maka ndị ọrịa nwere ike chọọ nleta ụlọ ọgwụ. maka nchịkwa site n'aka ndị ọkachamara ahụike. Na mgbakwunye na ọ dị mfe iji ya eme ihe, a na-egosi relugolix ka ọ dị elu na ịda mbà n'obi nke ọkwa testosterone ma e jiri ya tụnyere [leuprolide], usoro ọgwụgwọ ọzọ nke androgen na-eji na-agwọ ọrịa cancer prostate.

Relugolix bụ Gonadotropin na-ahapụ Hormone Nnabata antagonist. Usoro nke relugolix dị ka Gonadotropin Releasing Hormone Receptor Antagonist, na Cytochrome P450 3A Inducer, na Cytochrome P450 2B6 Inducer, na Ọrịa Cancer Resistance Protein Inhibitor, na P-Glycoprotein Inhibitor. Mmetụta physiologic nke relugolix bụ site na Mbelata Nzuzo GnRH.

Ọdịdị chemical